<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35507432</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1554-8635</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Autophagy</Title><ISOAbbreviation>Autophagy</ISOAbbreviation></Journal><ArticleTitle>Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>151</EndPage><MedlinePgn>126-151</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15548627.2022.2063003</ELocationID><Abstract><AbstractText>Macroautophagy/autophagy is an essential process for cellular survival and is implicated in many diseases. A critical step in autophagy is the transport of the transcription factor TFEB from the cytosol into the nucleus, through the nuclear pore (NP) by KPNB1/importin&#x3b2;1. In the C9orf72 subtype of amyotrophic lateral sclerosis-frontotemporal lobar degeneration (ALS-FTD), the hexanucleotide (G4C2)RNA expansion (HRE) disrupts the nucleocytoplasmic transport of TFEB, compromising autophagy. Here we show that a molecular chaperone, the SIGMAR1/Sigma-1 receptor (sigma non-opioid intracellular receptor 1), facilitates TFEB transport into the nucleus by chaperoning the NP protein (i.e., nucleoporin) POM121 which recruits KPNB1. In NSC34 cells, HRE reduces TFEB transport by interfering with the association between SIGMAR1 and POM121, resulting in reduced nuclear levels of TFEB, KPNB1, and the autophagy marker LC3-II. Overexpression of SIGMAR1 or POM121, or treatment with the highly selective and potent SIGMAR1 agonist pridopidine, currently in phase 2/3 clinical trials for ALS and Huntington disease, rescues all of these deficits. Our results implicate nucleoporin POM121 not merely as a structural nucleoporin, but also as a chaperone-operated signaling molecule enabling TFEB-mediated autophagy. Our data suggest the use of SIGMAR1 agonists, such as pridopidine, for therapeutic development of diseases in which autophagy is impaired.<b>Abbreviations</b>: ALS-FTD, amyotrophic lateral sclerosis-frontotemporal dementiaC9ALS-FTD, C9orf72 subtype of amyotrophic lateral sclerosis-frontotemporal dementiaCS, citrate synthaseER, endoplasmic reticulumGSS, glutathione synthetaseHRE, hexanucleotide repeat expansionHSPA5/BiP, heat shock protein 5LAMP1, lysosomal-associated membrane protein 1MAM, mitochondria-associated endoplasmic reticulum membraneMAP1LC3/LC3, microtubule-associated protein 1 light chain 3NP, nuclear poreNSC34, mouse motor neuron-like hybrid cell lineNUPs, nucleoporinsPOM121, nuclear pore membrane protein 121SIGMAR1/Sigma-1R, sigma non-opioid intracellular receptor 1TFEB, transcription factor EBTMEM97/Sigma-2R, transmembrane protein 97.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shao-Ming</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Cellular Pathobiology Section, Integrative Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 333 Cassell Drive, Baltimore, Maryland 21224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>China Medical University, Graduate Institute of Biomedical Sciences, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Brain Disease Center, China Medical University, No.91, Hsueh-Shih Road, Taichung city, 404333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, China Medical University Hospital, No.2, Yude Road, North District, Taichung city, 404333, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hsiang-En</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Cellular Pathobiology Section, Integrative Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 333 Cassell Drive, Baltimore, Maryland 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasui</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cellular Pathobiology Section, Integrative Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 333 Cassell Drive, Baltimore, Maryland 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geva</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Prilenia Therapeutics Development Ltd, Herzliya, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayden</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Prilenia Therapeutics Development Ltd, Herzliya, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maurice</LastName><ForeName>Tangui</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cozzolino</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Translational Pharmacology, CNR, Via del Fosso del Cavaliere 100, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Tsung-Ping</ForeName><Initials>TP</Initials><Identifier Source="ORCID">0000-0003-2384-6925</Identifier><AffiliationInfo><Affiliation>Cellular Pathobiology Section, Integrative Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 333 Cassell Drive, Baltimore, Maryland 21224, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K02 DA000206</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 DA000206</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Autophagy</MedlineTA><NlmUniqueID>101265188</NlmUniqueID><ISSNLinking>1554-8627</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028861">Nuclear Pore Complex Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>HD4TW8S2VK</RegistryNumber><NameOfSubstance UI="C483720">pridopidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106106">sigma-1 receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017480">Receptors, sigma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="Y">Autophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028861" MajorTopicYN="N">Nuclear Pore Complex Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="Y">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017480" MajorTopicYN="Y">Receptors, sigma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS/FTD</Keyword><Keyword MajorTopicYN="N">KPNB1/importin&#x3b2;1</Keyword><Keyword MajorTopicYN="N">SIGMAR1</Keyword><Keyword MajorTopicYN="N">TFEB</Keyword><Keyword MajorTopicYN="N">c9orf72</Keyword><Keyword MajorTopicYN="N">chaperone</Keyword><Keyword MajorTopicYN="N">nucleocytoplasmic transport</Keyword><Keyword MajorTopicYN="N">nucleoporin POM121</Keyword><Keyword MajorTopicYN="N">pridopidine</Keyword><Keyword MajorTopicYN="N">sigma-1 receptor</Keyword></KeywordList><CoiStatement>SMW, HEW, MC, TPS have no conflict of financial interest in the publication of this manuscript. MRH is CEO of Prilenia Neurotherapeutics, BV. MG is an employee of Prilenia Neurotherapeutics, Ltd, a subsidiary of Prilenia Therapeutics, BV. TM holds patents describing SIGMAR1/Sig1R ligands and did consultancies for Prilenia Therapeutics. TPS served from March, 2019- March, 2020, per NIDA/NIH approval, as a non-paid member of the Advisory Board to the Prilenia Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35507432</ArticleId><ArticleId IdType="pmc">PMC9809944</ArticleId><ArticleId IdType="doi">10.1080/15548627.2022.2063003</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256. DOI:10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268. DOI:10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507(7491):195&#x2013;200. DOI:10.1038/nature13124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13124</ArticleId><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S, Serrano A, Gerbino V, et al. Nuclear accumulation of mRNAs underlies G4C2-repeat-induced translational repression in a cellular model of C9orf72 ALS. J Cell Sci. 2015;128(9):1787&#x2013;1799. DOI:10.1242/jcs.165332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.165332</ArticleId><ArticleId IdType="pubmed">25788698</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525(7567):129&#x2013;133. DOI:10.1038/nature14974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14974</ArticleId><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525(7567):56&#x2013;61. DOI:10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, et al. Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173(4):958&#x2013;71 e17. DOI:10.1016/j.cell.2018.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.025</ArticleId><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck M, Forster F, Ecke M, et al. Nuclear pore complex structure and dynamics revealed by cryoelectron tomography. Science. 2004;306(5700):1387&#x2013;1390. DOI:10.1126/science.1104808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1104808</ArticleId><ArticleId IdType="pubmed">15514115</ArticleId></ArticleIdList></Reference><Reference><Citation>Amlacher S, Sarges P, Flemming D, et al. Insight into structure and assembly of the nuclear pore complex by utilizing the genome of a eukaryotic thermophile. Cell. 2011;146(2):277&#x2013;289. DOI:10.1016/j.cell.2011.06.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.06.039</ArticleId><ArticleId IdType="pubmed">21784248</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoelz A, Glavy JS, Beck M.. Toward the atomic structure of the nuclear pore complex: when top down meets bottom up. Nat Struct Mol Biol. 2016;23(7):624&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5156573</ArticleId><ArticleId IdType="pubmed">27273515</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Lagier-Tourenne C. Nuclear pores: the gate to neurodegeneration. Nat Neurosci. 2018;21(2):156&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">29371653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LR, Duan L, Bowen K, et al. C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. Elife. 2020;9. DOI:10.7554/eLife.51685</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.51685</ArticleId><ArticleId IdType="pmc">PMC7051184</ArticleId><ArticleId IdType="pubmed">32119645</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Zaepfel BL, Hayes L, et al. G4C2 repeat RNA initiates a POM121-mediated reduction in specific nucleoporins in C9orf72 ALS/FTD. Neuron. 2020;107(6):1124&#x2013;40 e11. DOI:10.1016/j.neuron.2020.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.06.027</ArticleId><ArticleId IdType="pmc">PMC8077944</ArticleId><ArticleId IdType="pubmed">32673563</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Bravo V, Pippa R, Song WM, et al. Nuclear pores promote lethal prostate cancer by increasing POM121-driven E2F1, MYC, and AR nuclear import. Cell. 2018;174(5):1200&#x2013;15 e20. DOI:10.1016/j.cell.2018.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.07.015</ArticleId><ArticleId IdType="pmc">PMC6150493</ArticleId><ArticleId IdType="pubmed">30100187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Saul A, Roon P, et al. Activation of the molecular chaperone, sigma 1 receptor, preserves cone function in a murine model of inherited retinal degeneration. Proc Natl Acad Sci U S A. 2016;113(26):E3764&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4932934</ArticleId><ArticleId IdType="pubmed">27298364</ArticleId></ArticleIdList></Reference><Reference><Citation>Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science. 1988;240(4849):219&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">2832949</ArticleId></ArticleIdList></Reference><Reference><Citation>Graybiel AM, Besson MJ, Weber E. Neuroleptic-sensitive binding sites in the nigrostriatal system: evidence for differential distribution of sigma sites in the substantia nigra, pars compacta of the cat. J Neurosci. 1989;9(1):326&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570010</ArticleId><ArticleId IdType="pubmed">2563278</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder SH, Largent BL. Receptor mechanisms in antipsychotic drug action: focus on sigma receptors. J Neuropsychiatry Clin Neurosci. 1989;1(1):7&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">2577720</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SB, Wang J, Cui X, et al. Sigma 1 receptor: a novel therapeutic target in retinal disease. Prog Retin Eye Res. 2018;67:130&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6557374</ArticleId><ArticleId IdType="pubmed">30075336</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambo DO, Lin M, Owens A, et al. The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission. Nat Commun. 2017;8(1):2228. DOI:10.1038/s41467-017-02087-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02087-x</ArticleId><ArticleId IdType="pmc">PMC5738444</ArticleId><ArticleId IdType="pubmed">29263318</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov TA, Epstein ML, Andersen KA, et al. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience. 2010;167(2):247&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862368</ArticleId><ArticleId IdType="pubmed">20167253</ArticleId></ArticleIdList></Reference><Reference><Citation>Francardo V, Bez F, Wieloch T, et al. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain. 2014;137(Pt 7):1998&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">24755275</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HR, Zheng S, Gurpinar E, et al. Crystal structure of the human sigma1 receptor. Nature. 2016;532(7600):527&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5550834</ArticleId><ArticleId IdType="pubmed">27042935</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouzier L, Couly S, Roques C, et al. Sigma-1 (sigma1) receptor activity is necessary for physiological brain plasticity in mice. Eur Neuropsychopharmacol. 2020;39:29&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">32893057</ArticleId></ArticleIdList></Reference><Reference><Citation>Rennekamp AJ, Huang XP, Wang Y, et al. sigma1 receptor ligands control a switch between passive and active threat responses. Nat Chem Biol. 2016;12(7):552&#x2013;558. DOI:10.1038/nchembio.2089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.2089</ArticleId><ArticleId IdType="pmc">PMC4912403</ArticleId><ArticleId IdType="pubmed">27239788</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontanilla D, Johannessen M, Hajipour AR, et al. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323(5916):934&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947205</ArticleId><ArticleId IdType="pubmed">19213917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhemkov V, Ditlev JA, Lee WR, et al. The role of sigma 1 receptor in organization of endoplasmic reticulum signaling microdomains. Elife. 2021;10. DOI:10.7554/eLife.65192.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.65192</ArticleId><ArticleId IdType="pmc">PMC8112866</ArticleId><ArticleId IdType="pubmed">33973848</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007;131(3):596&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">17981125</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov TA, Epstein M, Guo LW. Subcellular localization of the sigma-1 receptor in retinal neurons - an electron microscopy study. Sci Rep. 2015;5:10689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649997</ArticleId><ArticleId IdType="pubmed">26033680</ArticleId></ArticleIdList></Reference><Reference><Citation>Goguadze N, Zhuravliova E, Morin D, et al. Sigma-1 receptor agonists induce oxidative stress in mitochondria and enhance complex I activity in physiological condition but protect against pathological oxidative stress. Neurotox Res. 2019;35(1):1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">29127580</ArticleId></ArticleIdList></Reference><Reference><Citation>Su TP, Su TC, Nakamura Y, et al. The sigma-1 receptor as a pluripotent modulator in living systems. Trends Pharmacol Sci. 2016;37(4):262&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4811735</ArticleId><ArticleId IdType="pubmed">26869505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PT, Lievens JC, Wang SM, et al. Sigma-1 receptor chaperones rescue nucleocytoplasmic transport deficit seen in cellular and Drosophila ALS/FTD models. Nat Commun. 2020;11(1):5580. DOI:10.1038/s41467-020-19396-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19396-3</ArticleId><ArticleId IdType="pmc">PMC7642387</ArticleId><ArticleId IdType="pubmed">33149115</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Olivan S, Rando A, et al. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics. 2012;9(4):814&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480575</ArticleId><ArticleId IdType="pubmed">22935988</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyrskyluoto A, Pulli I, Tornqvist K, et al. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-kappaB pathway. Cell Death Dis. 2013;4:e646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674377</ArticleId><ArticleId IdType="pubmed">23703391</ArticleId></ArticleIdList></Reference><Reference><Citation>Peviani M, Salvaneschi E, Bontempi L, et al. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiol Dis. 2014;62:218&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141020</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2021;16(4):373&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">33070647</ArticleId></ArticleIdList></Reference><Reference><Citation>Monnet FP, de Costa BR, Bowen WD, et al. Differentiation of sigma ligand-activated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices. Br J Pharmacol. 1996;119(1):65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1915737</ArticleId><ArticleId IdType="pubmed">8872358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron R, de Montigny C, Debonnel G. Biphasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate. Naunyn Schmiedebergs Arch Pharmacol. 1995;351(3):252&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">7609778</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry. 2004;37 Suppl 3(S 3):S214&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15547788</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermack JE, Debonnel G. Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus. Synapse. 2005;55(1):37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">15499608</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilmann R, McGarry A, Grachev ID, et al. Safety and efficacy of pridopidine in patients with Huntington&#x2019;s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18(2):165&#x2013;176. DOI:10.1016/S1474-4422(18)30391-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30391-0</ArticleId><ArticleId IdType="pubmed">30563778</ArticleId></ArticleIdList></Reference><Reference><Citation>McGarry A, Auinger P, Kieburtz K, et al. Additional safety and exploratory efficacy data at 48 and 60 months from open-HART, an open-label extension study of pridopidine in Huntington disease. J Huntingtons Dis. 2020;9(2):173&#x2013;184. DOI:10.3233/JHD-190393.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-190393</ArticleId><ArticleId IdType="pubmed">32508327</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesei A, Cortesi M, Zamagni A, et al. Sigma receptors as endoplasmic reticulum stress &#x201c;Gatekeepers&#x201d; and their modulators as emerging new weapons in the fight against cancer. Front Pharmacol. 2018;9:711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6048940</ArticleId><ArticleId IdType="pubmed">30042674</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesei A, Cortesi M, Pignatta S, et al. Anti-tumor efficacy assessment of the sigma receptor pan modulator RC-106. A promising therapeutic tool for pancreatic cancer. Front Pharmacol. 2019;10:490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6530361</ArticleId><ArticleId IdType="pubmed">31156430</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagarde F, Beausoleil C, Belcher SM, et al. Non-monotonic dose-response relationships and endocrine disruptors: a qualitative method of assessment. Environ Health. 2015;14:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4429934</ArticleId><ArticleId IdType="pubmed">25971433</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong WC, Yano H, Hiranita T, et al. The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats. J Biol Chem. 2017;292(27):11250&#x2013;11261. DOI:10.1074/jbc.M116.774075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.774075</ArticleId><ArticleId IdType="pmc">PMC5500793</ArticleId><ArticleId IdType="pubmed">28495886</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano H, Bonifazi A, Xu M, et al. Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays. Neuropharmacology. 2018;133:264&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858991</ArticleId><ArticleId IdType="pubmed">29407216</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhemkov V, Geva M, Hayden MR, et al. Sigma-1 receptor (S1R) interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases. Int J Mol Sci. 2021;22(8):4082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8071319</ArticleId><ArticleId IdType="pubmed">33920913</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston TH, Geva M, Steiner L, et al. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Mov Disord. 2019;34(5):708&#x2013;716. DOI:10.1002/mds.27565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27565</ArticleId><ArticleId IdType="pubmed">30575996</ArticleId></ArticleIdList></Reference><Reference><Citation>Geva M, Kusko R, Soares H, et al. Pridopidine activates neuroprotective pathways impaired in huntington disease. Hum Mol Genet. 2016;25(18):3975&#x2013;3987. DOI:10.1093/hmg/ddw238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw238</ArticleId><ArticleId IdType="pmc">PMC5291233</ArticleId><ArticleId IdType="pubmed">27466197</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Miralles M, Geva M, Tan JY, et al. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2017;2(23). DOI:10.1172/jci.insight.95665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.95665</ArticleId><ArticleId IdType="pmc">PMC5752291</ArticleId><ArticleId IdType="pubmed">29212949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryskamp D, Wu L, Wu J, et al. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer&#x2019;s disease by acting on the sigma-1 receptor. Neurobiol Dis. 2019;124:489&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363865</ArticleId><ArticleId IdType="pubmed">30594810</ArticleId></ArticleIdList></Reference><Reference><Citation>Francardo V, Geva M, Bez F, et al. Pridopidine induces functional neurorestoration Via the sigma-1 receptor in a mouse model of parkinson&#x2019;s disease. Neurotherapeutics. 2019;16(2):465&#x2013;479. DOI:10.1007/s13311-018-00699-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-018-00699-9</ArticleId><ArticleId IdType="pmc">PMC6554374</ArticleId><ArticleId IdType="pubmed">30756361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu A, Gradus T, Altman T, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1(G93A) model. Cell Death Dis. 2019;10(3):210. DOI:10.1038/s41419-019-1451-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1451-2</ArticleId><ArticleId IdType="pmc">PMC6397200</ArticleId><ArticleId IdType="pubmed">30824685</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddings CR, Arbez N, Akimov S, et al. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiol Dis. 2019;129:118&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6996243</ArticleId><ArticleId IdType="pubmed">31108174</ArticleId></ArticleIdList></Reference><Reference><Citation>Naia L, Ly P, Mota SI, et al. The sigma-1 receptor mediates pridopidine rescue of mitochondrial function in huntington disease models. Neurotherapeutics. 2021;18:1017&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423985</ArticleId><ArticleId IdType="pubmed">33797036</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenkman M, Geva M, Gershoni-Emek N, et al. Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the Sigma-1 receptor. J Neurochem. 2021;158:467&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">33871049</ArticleId></ArticleIdList></Reference><Reference><Citation>McGarry A, Leinonen M, Kieburtz K, et al. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. J Huntingtons Dis. 2020;9(4):371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836066</ArticleId><ArticleId IdType="pubmed">33164941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N, Noda T, Yoshimori T, et al. A protein conjugation system essential for autophagy. Nature. 1998;395(6700):395&#x2013;398. DOI:10.1038/26506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/26506</ArticleId><ArticleId IdType="pubmed">9759731</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FB, Almeida S, Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J. 2017;36(20):2931&#x2013;2950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641681</ArticleId><ArticleId IdType="pubmed">28916614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardiello M, Palmieri M, Di Ronza A, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473&#x2013;477. DOI:10.1126/science.1174447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1174447</ArticleId><ArticleId IdType="pubmed">19556463</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429&#x2013;1433. DOI:10.1126/science.1204592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1204592</ArticleId><ArticleId IdType="pmc">PMC3638014</ArticleId><ArticleId IdType="pubmed">21617040</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmieri M, Pal R, Nelvagal HR, et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat Commun. 2017;8:14338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5303831</ArticleId><ArticleId IdType="pubmed">28165011</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Friedrichsen HJ, Andrews S, et al. A TFEB nuclear export signal integrates amino acid supply and glucose availability. Nat Commun. 2018;9(1):2685. DOI:10.1038/s41467-018-04849-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04849-7</ArticleId><ArticleId IdType="pmc">PMC6041281</ArticleId><ArticleId IdType="pubmed">29992949</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham KM, Maulding K, Ruan K, et al. TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS. Elife. 2020;9. DOI:10.7554/eLife.59419.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.59419</ArticleId><ArticleId IdType="pmc">PMC7758070</ArticleId><ArticleId IdType="pubmed">33300868</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera RM, Stoykova S, Nicolay BN, et al. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature. 2015;524(7565):361&#x2013;365. DOI:10.1038/nature14587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14587</ArticleId><ArticleId IdType="pmc">PMC5086585</ArticleId><ArticleId IdType="pubmed">26168401</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreser A, Vollrath JT, Sechi A, et al. The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins. Cell Death Differ. 2017;24(10):1655&#x2013;1671. DOI:10.1038/cdd.2017.88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2017.88</ArticleId><ArticleId IdType="pmc">PMC5596426</ArticleId><ArticleId IdType="pubmed">28622300</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollrath JT, Sechi A, Dreser A, et al. Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances. Cell Death Dis. 2014;5:e1290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4611717</ArticleId><ArticleId IdType="pubmed">24922074</ArticleId></ArticleIdList></Reference><Reference><Citation>Christ MG, Huesmann H, Nagel H, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity In Vitro and In Vivo. Cells. 2019;8(3):211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6468724</ArticleId><ArticleId IdType="pubmed">30832324</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Baskerville V, Zaepfel BL, et al. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Sci Transl Med. 2021;13(604). DOI:10.1126/scitranslmed.abe1923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abe1923</ArticleId><ArticleId IdType="pmc">PMC9022198</ArticleId><ArticleId IdType="pubmed">34321318</ArticleId></ArticleIdList></Reference><Reference><Citation>Montilla-Garcia A, Perazzoli G, Tejada MA, et al. Modality-specific peripheral antinociceptive effects of mu-opioid agonists on heat and mechanical stimuli: contribution of sigma-1 receptors. Neuropharmacology. 2018;135:328&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">29580951</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanida I, Ueno T, Kominami E. LC3 and Autophagy. Methods Mol Biol. 2008;445:77&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">18425443</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi W, Yan L, Liu Y, et al. Simvastatin aggravates impaired autophagic flux in NSC34-hSOD1G93A cells through inhibition of geranylgeranyl pyrophosphate synthesis. Neuroscience. 2019;409:130&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">31051215</ArticleId></ArticleIdList></Reference><Reference><Citation>Puertollano R, Ferguson SM, Brugarolas J, et al. The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. EMBO J. 2018;37(11). DOI:10.15252/embj.201798804</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798804</ArticleId><ArticleId IdType="pmc">PMC5983138</ArticleId><ArticleId IdType="pubmed">29764979</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Wang X, Li X, et al. Proteasome inhibition activates autophagy-lysosome pathway associated with TFEB dephosphorylation and nuclear translocation. Front Cell Dev Biol. 2019;7:170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6713995</ArticleId><ArticleId IdType="pubmed">31508418</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu UB, Ramachandran S, Hajipour AR, et al. Photoaffinity labeling of the sigma-1 receptor with N-[3-(4-nitrophenyl)propyl]-N-dodecylamine: evidence of receptor dimers. Biochemistry. 2013;52(5):859&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581363</ArticleId><ArticleId IdType="pubmed">23324054</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromek KA, Suchy FP, Meddaugh HR, et al. The oligomeric states of the purified sigma-1 receptor are stabilized by ligands. J Biol Chem. 2014;289(29):20333&#x2013;20344. DOI:10.1074/jbc.M113.537993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.537993</ArticleId><ArticleId IdType="pmc">PMC4106346</ArticleId><ArticleId IdType="pubmed">24847081</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsson SR, Roth J, Piller F, et al. Isolation and characterization of human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Major sialoglycoproteins carrying polylactosaminoglycan. J Biol Chem. 1988;263(35):18911&#x2013;18919.</Citation><ArticleIdList><ArticleId IdType="pubmed">3143719</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol. 2011;70(6):913&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">21842496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra R, Gadkari MBA VV, van Mierlo Cpm, et al. Mechanism of the small ATP-independent chaperone Spy is substrate specific. Nat Commun. 2021;12(1):851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7870927</ArticleId><ArticleId IdType="pubmed">33558474</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Y, Dryanovski DI, Kimura Y, et al. Cocaine-induced endocannabinoid signaling mediated by sigma-1 receptors and extracellular vesicle secretion. Elife. 2019;8:47209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6850780</ArticleId><ArticleId IdType="pubmed">31596232</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryskamp D, Wu J, Geva M, et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017;97(Pt A):46&#x2013;59. DOI:10.1016/j.nbd.2016.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.10.006</ArticleId><ArticleId IdType="pmc">PMC5214572</ArticleId><ArticleId IdType="pubmed">27818324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Goguadze N, Kimura Y, et al. Genomic action of sigma-1 receptor chaperone relates to neuropathic pain. Mol Neurobiol. 2021;58(6):2523&#x2013;2541. DOI:10.1007/s12035-020-02276-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02276-8</ArticleId><ArticleId IdType="pmc">PMC8128747</ArticleId><ArticleId IdType="pubmed">33459966</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>